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Abstract
The retinal venous pressure (RVP) can be measured non-invasively. While RVP is equal to or slightly above intraocular
pressure (IOP) in healthy people, it is often markedly increased in patients with eye or systemic diseases. Beside a
mechanical obstruction, the main cause of such an elevation is a local dysregulation of a retinal vein, particularly a
constriction induced by endothelin-1 (ET-1). A local increase of ET-1 can result from a high plasma level, as ET-1 can
diffuse from the fenestrated capillaries of the choroid into the optic nerve head (ONH), bypassing the blood retinal
barrier. A local increase can also result from increased local production either by a sick neighboring artery or retinal
tissue. Generally, the main factors increasing ET-1 are inflammations and hypoxia, either locally or in a remote organ.
RVP is known to be increased in patients with glaucoma, retinal vein occlusion (RVO), diabetic retinopathy,
high mountain disease, and primary vascular dysregulation (PVD). PVD is the major vascular component of
Flammer syndrome (FS). An increase of RVP decreases perfusion pressure, which heightens the risk for hypoxia. An
increase of RVP also elevates transmural pressure, which in turn heightens the risk for retinal edema. In patients with
RVO, a high level of RVP may not only be a consequence but also a potential cause of the occlusion; therefore, it risks
causing a vicious circle. Narrow retinal arteries and particularly dilated retinal veins are known risk indicators for future
cardiovascular events. As the major cause for such a retinal venous dilatation is an increased RVP, RVP may likely turn
out to be an even stronger predictor.
Keywords: Retinal venous pressure (RVP), Dilated retinal veins, Endothelin-1 (ET-1), Ophthalmodynamometry, Venous
constriction, Retinal vein occlusion (RVO), Diabetes mellitus, Glaucoma, Primary vascular dysregulation (PVD), Flammer
syndrome (FS), Predictive, preventive and personalized medicine
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Introduction
A few years ago, we described the local dysregulation of
retinal veins as a major cause of retinal vein occlusion
(RVO) [1]. Since providing this description, several reports
on retinal venous pressure (RVP) were published, motivat-
ing us to update the present knowledge about RVP in
terms of its regulation and role in different diseases.
Definition and measurement of retinal venous pressure
Alongside the retinal veins, there is a gradient of the
intravascular pressure of about 0.9 mmHg/mm. The
pressure is higher in the periphery than in the optic
nerve head (ONH) area where the vein exits the eye [2].
To measure the exact pressure in a vein, one needs to
insert a cannula intraluminally—a procedure not feasible
under clinical conditions. To estimate the approximate
pressure in the veins, intraocular pressure (IOP) is in-
creased until the vein pulsates. In this context, we define
RVP equal to the IOP where the vein at or close to the
ONH starts to pulsate. Pressure inducing a slight pulsa-
tion and pressure leading to (transient) collapse of the
vein occur within a certain range. Such methodological
discussion, although very important, is not a topic of this
review. In most available studies, the RVP was defined as
equal to the IOP inducing a slight pulsation. Why the vein
pulsates is still controversial [3]. A recent analysis attri-
butes it to the difference between IOP and cerebrospinal
fluid (CSF) pressure pulsations (Levine DH, Bebie H.
Phase and amplitude of spontaneous retinal vein pulsation:
an extended constant input - variable output model, sub-
mitted). Most studies used the Kontaktglas-Dynamometer
(also called ophthalmodynamometer) by Dr. Loew [4]
(IMEDOS Systems UG, Jena, Germany) (Fig. 1).
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Normal RVP values
The RVP generally is not (or is only for a short period of
time) lower than the IOP. If it were, the veins would col-
lapse. However, based on the Starling law, the trans-
mural venous pressure is probably temporarily negative
at the exit from the eye [2].
The central retinal vein leaves the eye through the an-
terior part of the optic nerve (ON) (Fig. 2), runs through
the CSF, and penetrates the meninges of the ON. There-
fore, RVP can also not be lower than the CSF pressure
around the ON [5].
In healthy subjects, a spontaneous retinal venous pul-
sation can often be observed, indicating that the RVP in
these subjects corresponds more or less to spontaneous
IOP. The ratio of healthy subjects with spontaneous
retinal venous pulsation varies from 75 % [6] to 98 %
[7]. It is important to note that RVP can be above IOP
even in presumed healthy subjects.
Mechanism leading to high RVP
There are a number of principal mechanisms leading to
a high RVP:
(1) IOP increase: High IOP automatically leads to
a high RVP. This is particularly relevant in
situations with a marked elevated IOP, such
as in patients with acute angle closure glaucoma.
(2) Increased CSF pressure: This is relevant in subjects
with CSF pressure higher than IOP. A number of
authors even use RVP to estimate CSF pressure [8].
Fig. 1 Measurement of retinal venous pressure by an ophthalmodynamometer. (Use of the device demonstrated on a co-worker of our team,
with written confirmed consent for publication.)
Fig. 2 Schematic representation of the blood vessels in the optic nerve (from [49], with permission). The central retinal vein runs through the
SAS; therefore, retinal venous pressure is equal or higher than the pressure in the SAS. Abbreviations: A arachnoid, C choroid, CRA central retinal
artery, Col. Br. collateral branches, CRV central retinal vein, D dura, LC lamina cribrosa, ON optic nerve, PCA posterior ciliary artery, PR prelaminar
region, R retina, S sclera, SAS subarachnoid space
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(3)Retinal venous thrombosis: If the outflow is
blocked, e.g., by a thrombus, the increased
resistance to flow increases RVP [9]. A real
thrombus, however, is—in contrast to earlier
assumptions—a rare event, and even in its event,
it may rather be secondary to blood flow
deceleration [1].
(4)Compression of the retinal vein by a distorted
lamina cribrosa: Such a compression could partly
explain the relationship between RVP and the stage
of glaucoma [10]. However, we agree with Hayreh
[11] that this mechanism may be an exception.
(5)Compression of a vein by a bypassing artery: At the
crossings in the retina and at the level of the lamina
cribrosa, arteries and veins come close to and even
share a common adventitia. It has therefore been
assumed that veins can be crushed mechanically by
sclerotic arteries and that this may even lead to a
vein occlusion [12]. We have postulated that this
narrowing of a vein may rather be due to active
constriction than due to a mechanical compression,
inter alia, mediated by molecular cross talk between
arteries and veins [1] (Fig. 3). Our hypothesis is
supported by findings with optical coherence
tomography (OCT) (Fig. 4) [13] and with adaptive
optics [14].
(6) Increased level of endothelin-1 (ET-1): The retinal
vessels lack autonomic innervation. The main
regulators of the size of retinal vessels are the
vascular endothelial cells (VEC). VEC dysfunction
occurs in many conditions, e.g., in glaucoma [15].
However, it is not likely that a general endotheliopathy
leads to such a localized constriction. Circulating
vasoactive hormones have limited impact on
the size of retinal vessels as long as the blood-retina
barrier (BRB) is intact. Vasoactive substances have,
however, a major impact if they reach retinal vessels
from the outside, which gives them direct contact
with the smooth muscle cells and pericytes. The
likelihood that vasoactive molecules, such as ET-1,
reach the vessels from the outside is particularly high
in and around the ONH. Together with the fact that
veins respond to a lower dose of ET-1 than arteries
[16], it is evident that retinal veins in the area of the
ONH are relatively often constricted.
Conditions leading to an ET-1 increase
ET-1 is a hormone which acts primarily locally. The
VEC release the major part of ET-1 abluminally for the
local smooth muscle cells and just a smaller part intra-
luminally, influencing the concentration in the circulat-
ing blood (Fig. 5).
While VEC produce ET-1 under a physiological condi-
tion, basically all cells produce ET-1 if they are under
stress. There are two main causes:
(1)Hypoxia: Hypoxia leads to an increase of
hypoxia-inducible factor-1 alpha (HIF-1-alpha), a
transcription factor. This leads to the upregulation
of several genes, such as erythropoietin, vascular
endothelial growth factor (VEGF), and ET-1 [17]
(Fig. 6). Hypoxia somewhere in the body can
increase ET-1 in the circulating blood and thereby
induce a secondary vascular dysregulation in the eye
[18]. A local hypoxia in the eye also increases ET-1
in the eye. This explains why a bilateral internal
carotid artery stenosis can induce a central retinal
vein occlusion (CRVO) [19].
(2) Inflammations: Most types of inflammations,
particularly autoimmune-mediated inflammations
(such as giant cell arteritis [20]), lead to an increased
production of ET-1 and thereby induce secondary
vascular dysregulation in remote organs, particularly
in the eye. In addition, endothelin (ET) receptor
blockers have proven to have an anti-inflammatory
effect in uveitis [21].
Fig. 3 Arteriovenous crossing in a human retina (reproduced from [1]). Retinal arteries and veins are very close both in the optic nerve head and
at the arteriovenous crossing in the retina. This allows molecular cross talk between arteries and veins in these specific locations. Left: microscopic
view of a histologic specimen. Right: schematic representation of the feasibility of a molecular interference. In physiological conditions, the locally
produced endothelin-1 has an effect just on the underlying smooth muscle cells. This is different under pathological conditions (see also Fig. 8)
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The functional local constriction of the retinal veins
A local constriction of retinal veins in the area of the
ONH increases RVP. Such a local constriction can be in-
duced by a local increase of ET-1. As already mentioned,
there are three potential sources of ET reaching the
retinal veins from the outside (Fig. 7).
(1)Circulating blood: The ET in the blood can directly
reach the smooth muscle cells of retinal vessels with
three modalities: (a) diffusion from fenestrated
capillaries of the choroid into the ONH, (b)
diffusion from the microvessels of the prelaminar
portion of the ONH because these vessels lack
Fig. 5 Release of endothelin-1 (ET-1). The vascular endothelial cells release the major part of ET-1 abluminally (for local action) and a smaller part
intraluminally, influencing the concentration in the circulating blood (from [50], with permission)
Fig. 4 Venous narrowing rather than compression at the arteriovenous crossings. a, f Fundus photographs of an arteriovenous (AV) crossing,
showing crossing phenomena (arrows). b, g Optical coherence tomography (OCT) sections obtained along the retinal veins at crossings. d, i OCT
sections obtained at the crossing, perpendicular to the retinal veins. c, e, h, j OCT images with indications of vascular outlines from the upper
OCT images. a–e An AV crossing that shows concealment. The retinal vein shows focal narrowing of the lumen at the crossing. However, the
vein does not exhibit signs of compression or flattening. The venous lumen is round, even just under the artery. f–j An AV crossing that shows
severe tapering. On fundus photographs, the bloodstream seems to be extremely narrow in the area of the crossing site. OCT sections reveal that
the actual venous lumen is larger than portrayed by fundus photograph and maintains a round shape. Red lines indicate arterial outlines, and blue
lines indicate venous outlines. (Reproduced from [13], with permission)
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normal properties of blood-brain barrier [22],
and (c) diffusion from local vessels in case of a
breakdown of the BRB. Therefore, an increase
of ET concentration in the circulating blood has
an impact on the retinal veins in healthy eyes
and an even greater impact in the presence of
local pathology.
(2)Diseased arteries: These can produce increased
amounts of ET-1. One part of it is secreted
abluminally, reaching veins from the outside in areas
Fig. 7 Influence of endothelin-1 (ET-1) on blood vessels in the optic nerve head and adjacent retina (reproduced from [31]). (A) Circulating ET-1
reaches just the endothelial cells (A1) and has a more or less neutral effect on the size of the vessels. If the blood-brain barrier is disrupted (A2), it
reaches the vascular smooth muscle cells directly and induces vasoconstriction. (B) Hypoxic retina produces ET-1, which diffuses also to neighboring
vessels. (C) ET-1 diffuses from fenestrated capillaries of the choroid into the optic nerve head and adjacent retina. This can induce a local constriction
of the veins and in turn increase retinal venous pressure
Fig. 6 Hypoxia-inducible factor-1 alpha (HIF-1-alpha). If oxygen concentration in a cell is lowered, less HIF-1 alpha is oxidized and degraded. Thus,
more HIF-1 alpha can move into the nucleus, where it acts as a transcription factor for vascular endothelial growth factor, endothelin-1, and
others (from [50], with permission)
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where the arteries and veins are close, i.e., in the
ONH and at the arteriovenous crossings (Fig. 8 (left)).
(3)Hypoxic neighboring tissue (Fig. 8 (right)): Hypoxia
increases ET-1 in any tissue including the eye. This
explains why disturbed ocular blood flow due to
arterial diseases can lead to a secondary increase of
RVP or even to RVO [19].
Increased RVP in different diseases
Available studies on RVP are still limited; therefore,
the behavior of RVP in most diseases is still un-
known. In the following sections, we summarize exist-
ing information.
Retinal vein occlusion
RVO (Fig. 9) occur in older subjects with risk factors,
such as arterial hypertension or increased IOP, and in
younger subjects, particularly those suffering from Flam-
mer syndrome (FS) [23].
RVP is increased in eyes with RVO [24], more in the
ischemic than the non-ischemic type [25]. Surprisingly,
however, RVP is also often increased in the clinically
non-affected fellow eye of such patients [26]. This can
be explained by the increased plasma ET-1 of such pa-
tients [27, 28]. The role of ET-1 is further supported by
the observation that calcium channel blockers (CCB)
decrease RVP [29]. The ET receptor type A is a G-
protein-coupled receptor. Its stimulation leads to both
an influx of calcium from the outside of the cell and to a
liberation of calcium from the internal storages. The
CCB inhibit the first component (Fig. 10) and thereby
reduce, but do not totally eliminate, the vasoconstrictive
effect of ET-1.
We assume that RVP slowly increases in patients de-
veloping RVO (as a consequence of a local vein constric-
tion) and thereby progressively decreases perfusion
pressure (PP). If PP drops below a critical limit, the hyp-
oxic retina starts to further increase the local ET-1 level,
with the danger for a vicious circle that includes a fur-
ther decrease of PP and a breakdown of the BRB [30].
This in turn leads to retinal hemorrhages [31] and
retinal edema. The hypothetical relationship between
ET-1, RVP, and RVO is depicted in Fig. 11.
Diabetes mellitus
Patients with diabetes mellitus (DM) often have an in-
creased level of ET-1 [32], retinal vessel tortuosity [33],
and dilated retinal veins [34]. Recently, it has been re-
ported that DM patients with diabetic retinopathy (DR)
have higher RVP than DM patients without DR and
healthy controls (Fig. 12) [35]. Although the causal rela-
tionship is not yet clear, ET-1 most probably plays a cru-
cial role. This increased RVP reduces PP and therefore
increases the risk for hypoxia contributing to a vicious
Fig. 8 Schematic representation of an arteriovenous crossing in retina in pathological conditions (reproduced from [1]). Left: a diseased artery
produces a higher amount of endothelin-1 (ET-1) inducing a venous constriction. Right: local hypoxia further contributes to the ET-1 level and to
the constriction of the vein. This can eventually lead to an RVO
Fig. 9 Clinical picture of retinal vein occlusion
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circle. Furthermore, high RVP increases transmural pres-
sure and therefore amplifies the risk for retinal edema.
Glaucoma
A number of studies have shown that a reduced PP and
increased fluctuation of PP are risk factors for glaucoma
progression [36]. For the calculation of PP, RVP was
assumed to be equal to IOP in most studies. Meanwhile,
it has been shown that in the majority of glaucoma pa-
tients, RVP is far above IOP [37]; therefore, the PP in such
cases is much lower than was previously assumed [10].
Healthy subjects with FS have slightly higher RVP than
healthy subjects without FS. In glaucoma patients, this
difference is even larger. The difference between IOP
Fig. 10 Stimulation of endothelin receptors. Endothelin stimulates the G-coupled endothelin receptors A. This leads to both opening of the
calcium channels and liberation of calcium from internal stores (from [51], with permission)
Fig. 11 The role of endothelin and retinal venous pressure in the pathogenesis of retinal vein occlusion (RVO). The scheme indicates the influence of
ET-1 on RVP. Increased RVP reduces PP. If this reduction is not compensated enough by arterial vasodilation, hypoxia will result, inducing possibly a
vicious circle that potentially ends in the clinical picture of an RVO. Abbreviations: ET-1 endothelin-1, RVP retinal venous pressure, PP perfusion pressure,
BRB blood-retina barrier
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and RVP was greatest in subjects suffering from both
glaucoma and FS [38] (Fig. 13).
Interestingly, the RVP in glaucomatous eyes with splinter
hemorrhages is not increased [39]. This supports our hy-
pothesis that these hemorrhages are not due to ruptures of
vessels but rather a consequence of a locally disturbed BRB
[31]. Indeed, the difference between brachial arterial blood
pressure and the retinal arterial blood pressure was higher
in the eyes with hemorrhages, indicating a higher blood
flow resistivity in the arteries somewhere between the heart
and the eye, most probably in the retroocular arteries [40].
This, in turn, increases the probability for overall hypoxia
in the eye and thereby a general increase of ET-1 in the
eye. This leads to a dysfunction of the BRB [31] but not
to a very local constriction of the retinal veins and there-
fore not necessarily to RVP increase.
High-altitude retinopathy
It has long been known that high altitude leads in
some subjects to a swollen ONH, dilated retinal
veins, and retinal hemorrhages [41]. These changes
have been assumed to be secondary to an increase of
intracranial pressure due to cerebral edema [42].
However, high altitudes lead to a mild but global
hypoxia and therefore to an increased ET-1 level in
the circulating blood [17, 43] and an RVP increase
[4]. Subjects with primary vascular dysregulation
(PVD), the vascular component of a FS, seem to
react more often and more intensively to high alti-
tudes [44]. We observed that a young lady with FS
repeatedly developed mild retinal venous stasis syn-
drome after ballooning. One day she tried to cross
the Alps in a balloon and lost consciousness before
reaching the required height.
Occlusion of a cilioretinal artery
An RVP increase has an impact on ONH perfusion (as
this area is drained by the central retinal vein) and is
therefore relevant for glaucoma. However, it influences
also a portion of the choroidal/retinal circulation in cases
with cilioretinal arteries. Indeed, an occlusion of a cilioret-
inal artery (CLRAO) has been reported in a patient with
increased RVP and FS [45] (Fig. 14), and central retinal
vein occlusions are sometimes associated with CLRAO.
Inflammatory diseases
Autoimmune diseases, such as giant cell arteritis, can
lead to both increased ET-1 levels and the upregulation
of ET receptors [20, 46]. Interestingly, in patients with
giant cell arteritis, an anterior ischemic optic neuropathy
(AION) occurs relatively often, although giant cell arter-
itis is a disease of the medium-sized and large arteries
Fig. 12 Retinal venous pressure (RVP) in patients with and without diabetic retinopathy (DR). RVP is increased in patients with DR but not in
diabetes patients without DR. RVP (mmHg) is plotted with the age (years). Straight lines indicate regression slopes. The black circle indicates the
control group, the red triangle represents the group diabetes patients without DR, and the green cross represents patients with DR (reproduced
from [35])
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and not of the arterioles. We have hypothesized that the
AION in such patients may not, or at least not always,
be the consequence of locally inflamed vessels but rather
the consequence of a secondary dysregulation of these
vessels, which is induced by ET-1 produced by remote
inflamed vessels [18, 31]. We recently had the chance to
observe a patient with Takayasu arteritis, a vasculitis pri-
marily affecting the aorta but also leading to increased
ET-1 plasma levels [47] and sometimes even to a pul-
monary hypertension [48]. During phases of acute in-
flammation, the ONH of our young patient turned pale
and the retinal veins in the area of the ONH markedly
constricted. After treatments of the inflammation with
an anti-IL6 agent, the vision improved, ONH colored
again, and the arteries but particularly the veins reached
nearly normal sizes again (Fig. 15).
Fig. 14 Occlusion of a cilioretinal artery (CLRAO) (from [45], with permission). Left: fundus with white ischemic retina with a “cherry-red spot”
appearance at the macula in an area supplied by a cilioretinal artery. Right: corresponding fluorescein angiogram
Fig. 13 The influence of Flammer syndrome (FS) on retinal venous pressure (RVP). Healthy subjects with FS have slightly higher RVP than healthy
subjects without FS. In glaucoma patients, this difference was even larger; the difference between IOP and RVP was greatest in subjects suffering from
both glaucoma and FS. Abbreviations: IOP intraocular pressure, RVP retinal venous pressure, POAG/FS+ patients with glaucoma and FS, POAG/FS-
patients with glaucoma and without FS, Healthy/FS+ healthy subjects with FS, Healthy/FS- healthy subjects without FS (reproduced from [38])
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Conclusions
Clinically, RVP can be measured at least approximatively.
Despite a number of limitations of a currently available
methodology to measure RVP, the ophthalmodynamome-
try produces helpful results. Based on the studies summa-
rized in this review, we can conclude that, beside
mechanical obstruction, the main cause of an RVP in-
crease is a local vein constriction, mainly mediated by ET-
1. In the long run, ET-1 not only constricts vessels but also
induces tissue remodeling of the vessel wall. Therefore,
the impediment to flow may then have functional and
structural components. ET-1 can diffuse from the circulat-
ing blood into the ONH via the choroid. ET-1, however,
can also diffuse from a diseased artery into the wall of a
neighboring vein. Finally, ET-1 is also produced locally
from hypoxic tissue. In most healthy subjects, RVP is close
to IOP or slightly above. RVP is, however, distinctly in-
creased in some ocular and systemic diseases, particularly
diseases accompanied by inflammation or hypoxia. This is
of major clinical relevance for the following reasons:
(1)High RVP reduces the PP and therefore reduces
circulation of both the retina and the ONH. The
reduction of retinal circulation is relevant for diseases,
such as RVO or DR. The reduction of ONH perfusion
contributes to glaucomatous damage.
(2)Augmented RVP increases transmural pressure
and therefore elevates the risk for retinal edema.
Unfortunately, very little has been known until now
about the relationship between retinal edema and
the RVP and whether the pharmacological
reduction of RVP reduces the edema.
(3) RVP might be a very sensitive marker for systemic
conditions associated with elevated ET-1. If this is
confirmed in future studies, RVP will be a sensitive
clinical marker for corresponding diseases and may
also be helpful for follow up.
(4) Patients with systemic hypertension have retinal veins
relatively wider to retinal arteries, and generally
narrow retinal arteries and particularly dilated retinal
veins are proven risk indicators for future
cardiovascular diseases [34]. The reason why dilated
veins are such a strong risk indicator was unexplained
until now. We assume that the dilatation of the retinal
veins is at least partly a consequence of a high RVP.
Therefore, a high RVP might turn out to be an even
stronger predictor for future cardiovascular events.
At present, we are still in the early stage of research in
this field. We suggest the following steps in order to
promote this research area:
– The methodology to measure RVP should and can
be improved.
– The relationship between RVP and ET-1 needs to be
established in experimental studies.
– Modalities (drugs) to reduce RVP should be further
evaluated, first in animals and then in humans.
– Whether the reduction of RVP improves prognosis
of diseases like glaucoma needs to be proven by
interventional studies.
– The prognostic power of an increased RVP should
be evaluated by epidemiological studies.
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Fig. 15 Changes of the diameter of the retinal veins over time. The temporal dynamic of the size of the veins is illustrated in a patient with
Takayasu arteritis. Left: during acute inflammation (of the aorta), the optic nerve head (ONH) of this young patient was pale, and the retinal veins
at the border of the ONH were markedly constricted. Right: after treatment of the inflammation, the ONH colored again, and the veins reached
nearly normal sizes. Arrows indicate one of these veins
Flammer and Konieczka The EPMA Journal  (2015) 6:21 Page 10 of 12
Authors’ contributions
JF and KK have both contributed to the manuscript. Both authors read and
approved the final manuscript.
Acknowledgements
We would like to acknowledge Mr. Thomas Navin Chackathayil for preparing
the figures.
Received: 7 September 2015 Accepted: 28 September 2015
References
1. Fraenkl SA, Mozaffarieh M, Flammer J. Retinal vein occlusions: the potential
impact of a dysregulation of the retinal veins. EPMA J. 2010;1(2):253–61.
2. Morgan WH, Yu DY, Cooper RL, Alder VA, Cringle SJ, Constable IJ. Retinal
artery and vein pressures in the dog and their relationship to aortic,
intraocular, and cerebrospinal fluid pressures. Microvasc Res. 1997;53(3):211–21.
3. Moret F, Reiff CM, Lagreze WA, Bach M. Quantitative analysis of fundus-
image sequences reveals phase of spontaneous venous pulsations. Trans Vis
Sci Tech. 2015;4(5):3
4. Baertschi M. Factors influencing retinal venous pressure. Doctoral thesis
SALUS University; 2015.
5. Stewart PS, Jensen OE, Foss AJ. A theoretical model to allow prediction of
the CSF pressure from observations of the retinal venous pulse.
Invest Ophthalmol Vis Sci. 2014;55(10):6319–23.
6. Legler U, Jonas JB. Frequency of spontaneous pulsations of the central
retinal vein in glaucoma. J Glaucoma. 2009;18(3):210–2.
7. Morgan WH, Hazelton ML, Azar SL, House PH, Yu DY, Cringle SJ, et al.
Retinal venous pulsation in glaucoma and glaucoma suspects.
Ophthalmology. 2004;111(8):1489–94.
8. Meyer-Schwickerath R, Stodtmeister R, Hartmann K. Non-invasive
determination of intracranial pressure. Physiological basis and practical
procedure. Klin Monbl Augenheilkd. 2004;221(12):1007–11.
9. Jonas JB. Ophthalmodynamometric assessment of the central retinal vein
collapse pressure in eyes with retinal vein stasis or occlusion. Graefes Arch
Clin Exp Ophthalmol. 2003;241(5):367–70.
10. Pillunat KR, Ventzke S, Spoerl E, Furashova O, Stodtmeister R, Pillunat LE.
Central retinal venous pulsation pressure in different stages of primary
open-angle glaucoma. Br J Ophthalmol. 2014;98(10):1374–8.
11. Hayreh SS. Prevalent misconceptions about acute retinal vascular occlusive
disorders. Prog Retin Eye Res. 2005;24(4):493–519.
12. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual
prognosis, and treatment modalities. Curr Eye Res. 2008;33(2):111–31.
13. Kumagai K, Tsujikawa A, Muraoka Y, Akagi-Kurashige Y, Murakami T,
Miyamoto K, et al. Three-dimensional optical coherence tomography
evaluation of vascular changes at arteriovenous crossings. Invest
Ophthalmol Vis Sci. 2014;55(3):1867–75.
14. Paques M, Brolly A, Benesty J, Lerme N, Koch E, Rossant F, et al. Venous nicking
without arteriovenous contact: the role of the arteriolar microenvironment in
arteriovenous nickings. JAMA Ophthalmol. 2015;133(8):947–50.
15. Buckley C, Hadoke PW, Henry E, O’Brien C. Systemic vascular endothelial cell
dysfunction in normal pressure glaucoma. Br J Ophthalmol.
2002;86(2):227–32.
16. Pellanda N, Flammer J, Haefliger IO. L-NAME- and U 46619-induced
contractions in isolated porcine ciliary arteries versus vortex veins.
Klin Monbl Augenheilkd. 2001;218(5):366–9.
17. Desai D, He S, Yorio T, Krishnamoorthy RR, Prasanna G. Hypoxia augments
TNF-alpha-mediated endothelin-1 release and cell proliferation in human
optic nerve head astrocytes. Biochem Biophys Res Commun.
2004;318(3):642–8.
18. Flammer J, Pache M, Resink T. Vasospasm, its role in the pathogenesis of
diseases with particular reference to the eye. Prog Retin Eye Res.
2001;20(3):319–49.
19. Garoon R, Carvounis PE. Central retinal vein occlusion with bilateral stenosis
of the internal carotid arteries. Lancet. 2015;385(9971):914.
20. Pache M, Kaiser HJ, Haufschild T, Lubeck P, Flammer J. Increased
endothelin-1 plasma levels in giant cell arteritis: a report on four patients.
Am J Ophthalmol. 2002;133(1):160–2.
21. Keles S, Halici Z, Atmaca HT, Yayla M, Yildirim K, Ekinci M, et al. The ocular
endothelin system: a novel target for the treatment of endotoxin-induced
uveitis with bosentan. Invest Ophthalmol Vis Sci. 2014;55(6):3517–24.
22. Hofman P, Hoyng P, vander Werf F, Vrensen GF, Schlingemann RO. Lack of
blood–brain barrier properties in microvessels of the prelaminar optic nerve
head. Invest Ophthalmol Vis Sci. 2001;42(5):895–901.
23. Konieczka K, Ritch R, Traverso CE, Kim DM, Kook MS, Gallino A, et al.
Flammer syndrome. EPMA J. 2014;5(1):11.
24. McAllister IL, Tan MH, Smithies LA, Wong WL. The effect of central retinal
venous pressure in patients with central retinal vein occlusion and a high
mean area of nonperfusion. Ophthalmology. 2014;121(11):2228–36.
25. Jonas JB, Harder B. Ophthalmodynamometric differences between ischemic
vs nonischemic retinal vein occlusion. Am J Ophthalmol. 2007;143(1):112–6.
26. Mozaffarieh M, Bartschi M, Henrich PB, Schoetzau A, Flammer J. Retinal
venous pressure in the non-affected eye of patients with retinal vein
occlusions. Graefes Arch Clin Exp Ophthalmol. 2014;252(10):1569–71.
27. Iannaccone A, Letizia C, Pazzaglia S, Vingolo EM, Clemente G, Pannarale MR.
Plasma endothelin-1 concentrations in patients with retinal vein occlusions.
Br J Ophthalmol. 1998;82(5):498–503.
28. Haufschild T, Prunte C, Messerli J, Flammer J. Increased endothelin-1 plasma
level in young adults with retinal vascular occlusive diseases. Klin Monbl
Augenheilkd. 2004;221(5):357–9.
29. Fang L, Turtschi S, Mozaffarieh M. The effect of nifedipine on retinal venous
pressure of glaucoma patients with the Flammer-Syndrome. Graefes Arch
Clin Exp Ophthalmol. 2015;253(6):935–9.
30. Kaur C, Foulds WS, Ling EA. Blood-retinal barrier in hypoxic ischaemic
conditions: basic concepts, clinical features and management. Prog Retin
Eye Res. 2008;27(6):622–47.
31. Flammer J, Konieczka K, Flammer AJ. The primary vascular dysregulation
syndrome: implications for eye diseases. EPMA J. 2013;4(1):14.
32. Xu W, Wang HY, Zhao XH, Wang PJ. Values of ocular hemodynamics and
serum endothelin-1 in the early diagnosis of diabetic retinopathy.
Zhonghua Yi Xue Za Zhi. 2013;93(1):37–40.
33. Sasongko MB, Wong TY, Nguyen TT, Cheung CY, Shaw JE, Kawasaki R, et al.
Retinal vessel tortuosity and its relation to traditional and novel vascular risk
markers in persons with diabetes. Curr Eye Res. 2015;1–7.
34. Flammer J, Konieczka K, Bruno RM, Virdis A, Flammer AJ, Taddei S. The eye
and the heart. Eur Heart J. 2013;34(17):1270–8.
35. Cybulska-Heinrich AK, Baertschi M, Loesche CC, Schoetzau A, Konieczka K,
Josifova T, et al. Patients with diabetic retinopathy have high retinal venous
pressure. EPMA J. 2015;6(1):5.
36. Lee J, Choi J, Jeong D, Kim S, Kook MS. Relationship between daytime
variability of blood pressure or ocular perfusion pressure and glaucomatous
visual field progression. Am J Ophthalmol. 2015;160(3):522-37.e1.
37. Stodtmeister R, Ventzke S, Spoerl E, Boehm AG, Terai N, Haustein M, et al.
Enhanced pressure in the central retinal vein decreases the perfusion
pressure in the prelaminar region of the optic nerve head. Invest
Ophthalmol Vis Sci. 2013;54(7):4698–704.
38. Fang L, Baertschi M, Mozaffarieh M. The effect of Flammer-syndrome on
retinal venous pressure. BMC Ophthalmol. 2014;14:121.
39. Kim KE, Kim DM, Flammer J, Kim KN. Central retinal venous pressure in eyes
of normal-tension glaucoma patients with optic disc hemorrhage.
PLoS One. 2015;10(5):e0127920.
40. Flammer J, Orgul S, Costa VP, Orzalesi N, Krieglstein GK, Serra LM, et al. The
impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21(4):359–93.
41. Willmann G, Gekeler F, Schommer K, Bartsch P. Update on high altitude cerebral
edema including recent work on the eye. High Alt Med Biol. 2014;15(2):112–22.
42. Bosch MM, Barthelmes D, Landau K. High altitude retinal hemorrhages–an
update. High Alt Med Biol. 2012;13(4):240–4.
43. Mullner-Eidenbock A, Hauffschild T, Flammer J, Frisch H, Neupane P,
Waldhör T. Hoehenretinopathie und Endothelin-1. Oestereichische
Gesellschaft fuer Alpin und Hoehenmedizin. 2003:Jahrbuch: 127–41.
44. Mullner-Eidenbock A, Rainer G, Strenn K, Zidek T. High-altitude retinopathy
and retinal vascular dysregulation. Eye. 2000;14(Pt 5):724–9.
45. Konieczka K, Todorova MG, Chackathayil TN, Henrich PB. Cilioretinal artery
occlusion in a young patient with Flammer syndrome and increased retinal
venous pressure. Klin Monbl Augenheilkd. 2015;232(4):576–8.
46. Lozano E, Segarra M, Corbera-Bellalta M, Garcia-Martinez A, Espigol-Frigole
G, Pla-Campo A, et al. Increased expression of the endothelin system in
arterial lesions from patients with giant-cell arteritis: association between
elevated plasma endothelin levels and the development of ischaemic
events. Ann Rheum Dis. 2010;69(2):434–42.
47. Akazawa H, Ikeda U, Kuroda T, Shimada K. Plasma endothelin-1 levels in
Takayasu’s arteritis. Cardiology. 1996;87(4):303–5.
Flammer and Konieczka The EPMA Journal  (2015) 6:21 Page 11 of 12
48. Wang X, Dang A, Chen B, Lv N, Liu Q. Takayasu arteritis-associated
pulmonary hypertension. J Rheumatol. 2015;42(3):495–503.
49. Hayreh SS. Ocular vascular occlusive disorders: natural history of visual
outcome. Prog Retin Eye Res. 2014;41:1–25.
50. Flammer J, Mozaffarieh M, Bebie H. Basic sciences in ophthalmology. Berlin
Heidelberg: Springer; 2013.
51. Flammer J. Die Behandlung des Normaldruckglaukoms mit
Kalziumantagonisten. Search on Glaucoma. 1997;4:76–80.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Flammer and Konieczka The EPMA Journal  (2015) 6:21 Page 12 of 12
